Title:
TGFβ阻害剤を発現する遺伝的に改変された細胞であって、肺癌細胞である細胞
Document Type and Number:
Japanese Patent JP5079962
Kind Code:
B2
Abstract:
The present invention relates to compositions comprising a therapeutically effective amount of genetically modified cells containing a genetic constructs expressing a TGF² inhibitor effective to reduce expression of TGF², where the genetically modified cells are non-small cell lung cancer (NSCLC) cells or small cell lung cancer (SCLC) cells, and related methods.
Inventors:
Fakrai, Habib
Application Number:
JP2001572145A
Publication Date:
November 21, 2012
Filing Date:
March 30, 2001
Export Citation:
Assignee:
Novaks
International Classes:
A61K48/00; A61K31/7088; A61K31/7105; A61K35/42; A61K39/00; A61K39/395; A61P11/00; A61P35/00; A61P37/02; A61P37/04; A61P43/00; C12N15/00
Foreign References:
| WO1996002143A1 |
Other References:
澤井聡 外2名,特集 肺癌の形態と予後-予後を修飾する因子- 『細胞反応と予後 ―T細胞認識抗原をターゲットとした免疫療法―』,肺癌の臨床,日本,篠原出版,1999年 8月,Vol.2,No.3,P.391-397
Attorney, Agent or Firm:
Yoshiyuki Kawaguchi